ANTI–TUBERCULOSIS MEDICINES TECHNICAL SPECIFICATIONS, FIRST LINE DRUGS – ITB - IDA/FLD/2019/001

GLOBAL DRUG FACILITY

STBP | Stop TB Partnership
Eligibility criteria for submission of bids for anti-tuberculosis drugs

Only bidders with products in compliance with the GDF Quality Assurance Policy (see http://www.stoptb.org/gdf/drugsupply/quality_sourcing_process.asp) are eligible to participate in the ITB.

The requirements are as following:

A. Products pre-qualified by WHO under the WHO Prequalification Programme (WHO PQP)\(^1\); or
B. Products approved by a Stringent Regulatory Authority (SRA)\(^2\);
C. In the absence of products meeting the standards "A" and "B" as above, products recommended for use through a quality risk/benefit assessment process by the Expert Review Panel (ERP)\(^3\). These products are eligible for procurement for a limited period and under the following conditions:

1. The Finished Pharmaceutical Product (FPP) must be manufactured at an approved site as follows:
   - The site must have been inspected by WHO as a part of the WHO PQP (refer to http://apps.who.int/prequal/) and found to be operating at an acceptable level of compliance with WHO Good Manufacturing Practice (GMP) for the specific product; or
   - The site must have been inspected and found acceptable for the manufacture of the specific product by SRA defined as either: an International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) member country, an ICH observer or any country whose regulatory authority is associated with an ICH member through a legally binding mutual recognition agreement; or
   - The site must have been inspected and found acceptable for the manufacture of the specific product by inspectors of a regulatory authority participating in the Pharmaceutical Inspection Cooperation Scheme (PIC/S)

2. A product approval as described under either point "A" or "B" is pending, i.e. manufacturers have submitted relevant product dossiers and the dossiers have been accepted for assessment either by WHO PQP or SRA. Approvals under point "C" shall be limited to a maximum duration of 12 months in which manufacturers should obtain approval by WHO PQP or SRA.

Note: A bid submitted for a product for which the bidder has not received regulatory approval status as per GDF Quality Assurance policy and procedures, shall not be considered for the ITB evaluation.

---

1. [https://extranet.who.int/prequal/content/prequalified-lists/medicines](https://extranet.who.int/prequal/content/prequalified-lists/medicines)

2. [https://extranet.who.int/prequal/sites/default/files/documents/75%20SRA%20clarification_February2017_0.pdf](https://extranet.who.int/prequal/sites/default/files/documents/75%20SRA%20clarification_February2017_0.pdf)

# LIST OF PRODUCTS AND TECHNICAL SPECIFICATIONS

## SCHEDULE NO. 1:

**Oral solid dosage forms. Fixed dose combinations**

## ADULTS

1. **ITEM No. 1: 4FDC/ RHZE 150/75/400/275 (blister)**

   **General Description:** Fixed-dose combination of Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol 275mg tablets.

   **Primary packaging:** 28 tablets/blister

   **Secondary packaging:** pack of 24 blisters x 28 tablets.

2. **ITEM No. 2: 3FDC/ RHE 150/75/275 (blister)**

   **General Description:** Fixed-dose combination of Rifampicin 150mg/Isoniazid 75mg/Ethambutol 275mg tablets.

   **Primary packaging:** 28 tablets/blister

   **Secondary packaging:** pack of 24 blisters x 28 tablets.

3. **ITEM No. 3: 2FDC/ RH 150/75 (blister)**

   **General Description:** Fixed-dose combination of Rifampicin 150mg/Isoniazid 75mg tablets

   **Primary packaging:** 28 tablets/blister

   **Secondary packaging:** pack of 24 blisters x 28 tablets.

## CHILDREN

4. **ITEM No. 4: 3FDC/ RHZ 75/50/150 (blister)**

   **General Description:** Fixed-dose combination of Rifampicin 75mg/Isoniazid 50mg/Pyrazinamide 150mg dispersible tablets.

   **Primary packaging:** 28 or 10 tablets/blister

   **Secondary packaging:** pack of 3 blisters x 28 tablets or 10 blisters x 10 tablets
5. ITEM No. 5: 2FDC/ RH 75/50 (blister)

General Description: Fixed-dose combination of Rifampicin 75mg/Isoniazid 50mg dispersible tablets.

Primary packaging: 28 or 10 tablets/blister

Secondary packaging: pack of 3 blisters x 28 tablets or 10 blisters x 10 tablets

---

SCHEDULE NO. 2:

Oral solid dosage forms. Single dose formulations.

---

ADULTS

6. ITEM No. 1: Ethambutol 400 mg (blister)

General Description: Ethambutol 400mg tablets

Primary packaging: 28 tablets/blister

Secondary packaging: pack of 24 blisters x 28 tablets

7. ITEM No. 2: Isoniazid 300 mg (blister)

General Description: Isoniazid 300mg tablets

Primary packaging: 28 tablets/blister

Secondary packaging: pack of 24 blisters x 28 tablets

8. ITEM No. 3: Pyrazinamide 400 mg (blister)

General Description: Pyrazinamide 400mg tablets

Primary packaging: 28 tablets/blister

Secondary packaging: pack of 24 blisters x 28 tablets

9. ITEM No. 4: Pyrazinamide 500 mg (blister)

General Description: Pyrazinamide 500mg tablets

Primary packaging: 28 or 10 tablets/blister

Secondary packaging: pack of 24 blisters x 28 tablets or 10 blisters x 10 tablets
<table>
<thead>
<tr>
<th>Item No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Rifampicin 150 mg (blister)</td>
</tr>
<tr>
<td>6</td>
<td>Rifampicin 300 mg (blister)</td>
</tr>
<tr>
<td>7</td>
<td>Rifabutin 150 mg (blister/container)</td>
</tr>
<tr>
<td>8</td>
<td>Rifapentine 150 mg (blister)</td>
</tr>
<tr>
<td>9</td>
<td>Isoniazid 100 mg (blister)</td>
</tr>
<tr>
<td>10</td>
<td>Isoniazid 100 mg DT (blister/container)</td>
</tr>
</tbody>
</table>

**General Description:**
- Rifampicin 150mg tablets or capsules.
- Primary packaging: 10 tablets or capsules/blister.
- Secondary packaging: pack of 10 blisters x 10 tablets or capsules.

**Primary Description:**
- Rifampicin 300mg tablets or capsules.
- Primary packaging: 10 tablets or capsules/blister.
- Secondary packaging: pack of 10 blisters x 10 tablets or capsules.

**Primary Description:**
- Rifabutin 150mg capsules.
- Primary packaging: 100 capsules/HDPE container or 10 capsules/blister.
- Secondary packaging: 100 capsules/HDPE container or pack of 10 blisters x 10 capsules.

**Primary Description:**
- Rifapentine 150mg tablets.
- Primary packaging: 8 or 10 tablets/blister.
- Secondary packaging: pack of 3 blisters x 8 capsules or 10 blisters x 10 capsules.

**Children**

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Isoniazid 100 mg (blister)</td>
</tr>
<tr>
<td>10</td>
<td>Isoniazid 100 mg DT (blister/container)</td>
</tr>
</tbody>
</table>

**General Description:**
- Isoniazid 100mg tablets.
- Primary packaging: 10 tablets/blister.
- Secondary packaging: pack of 10 blisters x 10 tablets.

**General Description:**
- Isoniazid 100mg dispersible tablets.
- Primary packaging: 10 tablets/blister or HDPE container.
- Secondary packaging: pack of 10 blisters x 10 tablets or 100 tablets/HDPE container.
16. ITEM No.11: Ethambutol 100 mg (blister)

**General Description:** Ethambutol 100mg tablets.

**Primary packaging:** 10 tablets/blister.

**Secondary packaging:** pack of 10 blisters x 10 tablets.

17. ITEM No.12: Ethambutol 100 mg DT (blister/container)

**General Description:** Ethambutol 100mg dispersible tablets.

**Primary packaging:** 10 tablets/blister or 100 tablets/HDPE container.

**Secondary packaging:** pack of 10 blisters x 10 tablets or 100 tablets/HDPE container.

18. ITEM No. 13: Pyrazinamide 150 mg DT (blister/container)

**General Description:** Pyrazinamide 150mg dispersible tablets.

**Primary packaging:** 10 tablets/blister or 100 tablets/HDPE container.

**Secondary packaging:** pack of 10 blisters x 10 tablets or 100 tablets/HDPE container.

**SCHEDULE NO. 3:**

Stop TB patient kit

19. ITEM No. 1: Cat I & III Kit type A

**General Description:** Stop TB Cat. I + III Patient Kit type A containing

- 6 blisters of 4FDC R150/H75/Z400/E275 (28 tablets/blister)
- 12 blisters of 2FDC R150/H75 (28 tablets/blister)

**Technical Specifications:**

<table>
<thead>
<tr>
<th>Specifications of the outer box</th>
<th>Laminated, corrugated punched cardboard box</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimensions:</td>
<td></td>
</tr>
<tr>
<td>• Length: 220mm ±5mm</td>
<td></td>
</tr>
<tr>
<td>• Width: 115mm±5mm</td>
<td></td>
</tr>
<tr>
<td>• Height: 130mm±5mm</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specifications of the 4-FDC (RHZE) inner box</th>
<th>Laminated, corrugated punched cardboard box</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimensions:</td>
<td></td>
</tr>
<tr>
<td>• Length: 200mm ±5mm</td>
<td></td>
</tr>
<tr>
<td>• Width: 50mm±5mm</td>
<td></td>
</tr>
<tr>
<td>• Height: 120mm±5mm</td>
<td></td>
</tr>
</tbody>
</table>
Specifications of the 2 FDC (RH) inner box:

- Laminated, corrugated punched cardboard box
- Dimensions:
  - Length: 150mm ±5mm
  - Width: 60mm±5mm
  - Height: 85mm±5mm

**SCHEDULE NO. 4:**

**Other add-on agents**

20. **ITEM No.1: Pyridoxine 50 mg (blister)**

**General Description:** Pyridoxine hydrochloride 50mg tablets.

**Primary packaging:** 10 tablets/blister.

**Secondary packaging:** pack of 10 blisters x 10 tablets.

21. **ITEM No.2: Pyridoxine 100 mg (blister/container)**

**General Description:** Pyridoxine hydrochloride 100mg tablets.

**Primary packaging:** 10 tablets/blister or 250 tablets/HDPE container.

**Secondary packaging:** pack of 10 blisters x 10 tablets or 250 tablets /HDPE container.